ViewsML Raises $4.9M Seed

ViewsML, based in Vancouver, British Columbia, is a health technology company building a computational layer for biomarker discovery through AI-driven virtual staining. The company announced it has completed an oversubscribed $4.9M seed funding round.

Investors

The funding round was led by Wittington Ventures, a multi-stage investment platform. Additional investors included Continuum Health Ventures, Mayo Clinic, RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund.

ViewsML Use of Funds

ViewsML plans to use the capital to accelerate the commercialization of its AI-driven virtual biomarker staining platform, expand strategic partnerships, advance clinical validation of virtual biomarker panels, and grow its engineering, scientific, and commercial teams.

About ViewsML

Founded in 2026, ViewsML is led by CEO Kenneth To. The company is developing the world first virtual biomarker library, which utilizes artificial intelligence to extract per-cell spatial biomarker insights from routine pathology images, effectively transforming a traditionally laboratory-bound diagnostic process into a software-based workflow.

Funding Details

Company Website: https://viewsml.com

Company: ViewsML
Raised: $4.9M
Round: Seed
Funding Date: April 20, 2026
Lead Investor: Wittington Ventures
Additional Investors: Continuum Health Ventures, Mayo Clinic, RiSC Capital, Debiopharm, WUTIF, Defined, e-Fund
Company Website: www.viewsml.com
Software Category: Healthcare AI
Source: https://www.globenewswire.com/news-release/2026/04/20/3277170/0/en/viewsml-secures-funding-to-accelerate-commercialization-of-ai-driven-virtual-biomarker-staining-platform.html